Tirzepatide interacts with a defined set of drug classes, and is contraindicated in MTC/MEN2 history, pancreatitis history needs caution. Screening for these before the first dose prevents almost all serious events.
Interaction classes to screen
| Class | Concern | Action |
|---|---|---|
| Metabolic inhibitors | Raised plasma levels and exaggerated effect | Reduce dose or space administration |
| Metabolic inducers | Reduced exposure and treatment failure | Review response and adjust |
| Same-target agents | Additive pharmacology | Avoid duplicate therapy |
| Agents affecting the same organ system | nausea, diarrhoea, decreased appetite, injection-site reaction | Monitor and document |
Key takeaways
- Screen every new prescription against the patient's full medicine list.
- Common reactions, nausea, diarrhoea, decreased appetite, injection-site reaction, are amplified by interacting drugs.
- Document the interaction check in the dispensing record.
- Re-screen whenever another long-term medicine is added.
Monitoring in practice
Most interaction risk is manageable with a scheduled review after the onset window of early appetite change in 1–2 weeks and one further check at steady state. Patients on multiple chronic medicines benefit from an annual structured medication review.
Tirzepatide at a glance
| Attribute | Detail |
|---|---|
| Drug class | dual GIP and GLP-1 agonist |
| Common brand | Mounjaro / Zepbound |
| Licensed use | type 2 diabetes and obesity |
| Available strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Dosage form | prefilled pen |
| Typical onset | early appetite change in 1–2 weeks |
| Duration / dosing interval | weekly dosing, ~5-day half-life |
| Storage | 2–8 °C cold chain until first use |
